Hormonal
Women with diabetes face a 58% greater risk of coronary heart disease (CHD) mortality and a 13% greater risk of all-cause mortality compared to men with diabetes, indicating a significant sex-specific disparity in cardiovascular outcomes.
If you are a woman with diabetes, your risk of dying from heart disease is significantly higher than a man with diabetes. This means you should not just manage your blood sugar, but actively prioritize cardiovascular health with your doctor, potentially requiring more aggressive monitoring or prevention strategies than standard male-centric guidelines might suggest.
Compared with men with diabetes, women with diabetes had a 58% greater risk of CHD mortality, but only an 8% greater risk of stroke mortality (RRRCHD 1.58, 95% CI 1.32 to 1.90; P < 0.001; RRRstroke 1.08, 95% CI 1.01 to 1.15; P < 0.001). The pooled women-to-men RRR showed a 13% greater risk of all-cause mortality associated with diabetes in women than in men (RRR 1.13, 95% CI 1.07 to 1.19; P < 0.001).
Why this rating
Based on a systematic review and meta-analysis of 49 studies involving over 5 million participants.
Source
Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants
Yafeng Wang et al. · BMC Medicine · 2019
DOI 10.1186/s12916-019-1355-0
More from this paper
- There is no significant sex difference in the relative risk of cancer mortality associated with diabetes; the risk increase is comparable for both men and women.Strong
- Women with diabetes have a 30% greater excess risk of cardiovascular disease (CVD) mortality compared to men with diabetes, driven largely by a higher risk of coronary heart disease (CHD) mortality.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →